Francke, K.; Baumann, S.; Gashaw, I.; Klein, S.; Rohde, B.; Zolk, O.; Fischer, O.M.; Friedrich, C.
Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study. Pharmaceuticals 2025, 18, 758.
https://doi.org/10.3390/ph18050758
AMA Style
Francke K, Baumann S, Gashaw I, Klein S, Rohde B, Zolk O, Fischer OM, Friedrich C.
Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study. Pharmaceuticals. 2025; 18(5):758.
https://doi.org/10.3390/ph18050758
Chicago/Turabian Style
Francke, Klaus, Sybille Baumann, Isabella Gashaw, Stefan Klein, Beate Rohde, Oliver Zolk, Oliver M. Fischer, and Christian Friedrich.
2025. "Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study" Pharmaceuticals 18, no. 5: 758.
https://doi.org/10.3390/ph18050758
APA Style
Francke, K., Baumann, S., Gashaw, I., Klein, S., Rohde, B., Zolk, O., Fischer, O. M., & Friedrich, C.
(2025). Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study. Pharmaceuticals, 18(5), 758.
https://doi.org/10.3390/ph18050758